复星医药芦沃美替尼片新增适应症临床试验获批

Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration to conduct clinical trials for the drug Rumaine (generic name: Luwotametin tablets) in combination with Anlotinib for advanced non-small cell lung cancer patients with KRAS mutations [1] Group 1 - The drug Luwotametin is a selective MEK1/2 inhibitor [1] - Luwotametin has already been approved for two indications in mainland China, including treatment for Langerhans cell histiocytosis (LCH) and for pediatric patients with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) [1] - The company plans to initiate Phase II clinical trials for the drug once conditions are met [1]